---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-064106"
form_type: "8-K"
ticker: "BNBX"
cik: "0000744452"
company_name: "BNB PLUS CORP."
filed_at: "2025-06-30T23:59:59+00:00"
generated_at: "2026-05-18T15:08:48.686836+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Applied DNA restructures to focus on LineaRx; cuts 27% of staff, shuts clinical lab

## Summary
- Workforce reduction of 27% (projected 23% payroll cut); ceases operations at Applied DNA Clinical Labs.
- One-time charges of ~$300k; majority of costs expected by Sept 30, 2025.
- CEO Judy Murrah takes 15% salary reduction to $340k/year.
- Company ends May 2025 with ~$4.8M cash; cumulative headcount reduction of 39% since Dec 2024.
- Restructuring positions LineaRx synthetic DNA manufacturing as sole focus.

## SEC filing metadata
- accession: 0001104659-25-064106
- form_type: 8-K
- ticker: BNBX
- cik: 0000744452
- company_name: BNB PLUS CORP.
- filed_at: 2025-06-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.05, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744452/000110465925064106/0001104659-25-064106-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744452/000110465925064106/tm2519488d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-064106
- JSON: https://secwatch.observer/filing/0001104659-25-064106.json
- Plain text: https://secwatch.observer/filing/0001104659-25-064106.txt

## Key facts
- Restructurings & Charges
  BNB PLUS CORP. announced a restructuring with charges of approximately $300 thousand in one-time charges affecting Applied DNA Clinical Labs (ADCL); company-wide workforce reduction (approximately 27% of headcount).
  - Type: restructuring
  - Charge: approximately $300 thousand in one-time charges
  - Affected area: Applied DNA Clinical Labs (ADCL); company-wide workforce reduction
  - Headcount: approximately 27% of headcount
  source text: Company’s former Chairman and Chief Executive Officer. The projected annual payroll savings is expected to be partially offset by approximately three hundred thousand dollars ($300,000) in one-time charges related to the workforce reduction and ceasing of operations at ADCL, primarily for separation benefits. The Company expects to incur the majority of
  evidence_url: https://www.sec.gov/Archives/edgar/data/744452/000110465925064106/0001104659-25-064106-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.